Abbott/Millennium Metabolic Disease Deal Aims For 4-5 Drugs In 10 Years
Executive Summary
Abbott expects to bring four to five obesity and diabetes drugs to the market in the next 10 years under an alliance announced with Millennium Pharmaceuticals.
You may also be interested in...
Aventis Spins Off Gene Therapy, Returns p53 Commercial Rights To Introgen
Aventis is reducing its direct involvement in gene therapy research with a spin off of its Gencell division and return of responsibility for worldwide development of p53 gene products to Texas biotech firm Introgen.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011